Laboratoire Theramex

Laboratoire Theramex S.a.

Laboratorie Theramek

Jacques Paris

Jean-Louis Thomas

Michel Lanquetin

Remi Delansorne

Jean-Claude Pascal

Jean Lafay

Alain Piasco

Bertrand Villet

Jean Louis Thomas

Anny Lanquetin, Legal Representative

R&eacute;mi Delansorne

Jean-Philippe Lanquetin, Legal Representative

Elsimar Coutinho

Georges Gray

A method of preventing estrogen deficiencies and osteoporosis in menopausal women by continuously orally administering without interruption to menopausal women in need thereof an amount of 0.3 to 3 mg of 17&#x3b2;-estradiol or esters thereof and 0.3 to 1.25 mg of nomegestrol or esters thereof in an amount sufficient to prevent said problems.

Hormonal composition and its use

Hormonal composition based on a progestational agent and an oestrogen and use thereof

A method of achieving contraception in a woman which comprises administering orally to said woman an estroprogestative composition comprising nomegestrol acetate and an estrogen is provided.

Contraception method

The present invention relates to the field of therapeutic chemistry and more especially to the realization of new galenic forms intended to be applied on the skin. More particularly it relates to a topical hormonal composition with a systemic effect for the hormonal treatment of the perimenopause and of the menopause as well as for the treatment of the ovarian hormonal deficiencies in women with amenorrhea, characterized in that it comprises, as active ingredients, a progestogen derived from 19-nor progesterone and estradiol or one of its derivatives, a vehicle which allows the systemic passage of said active ingredients, chosen from the group constituted by a solubilizing agent, an absorption promoting agent, a film-forming agent, a gelling agent and their mixtures, in combination or in a mixture with suitable excipients for the realization of a gelled and/or film-forming pharmaceutical form.

Topical oestroprogestational compositions with a systemic effect

The present invention relates to the field of chemistry and more particularly to that of therapeutic chemistry. The invention relates more particularly to novel contraceptive compositions formed from a progestative agent and an oestrogen. The invention relates specifically to novel pharmaceutical contraceptive compositions, characterized in that they contain, as active ingredients, a nomegestrol ester and oestradiol, in combination or admixture with an inert, non-toxic, pharmaceutically-acceptable vehicle or diluent which is suitable for oral administration.

Contraceptive medicine based on a progestational agent and an oestrogen and preparation method

A method of treating estrogenic deficiencies in women while further avoiding the appearance of osteoporosis, withdrawal bleeding and cardiovascular diseases in post-menopausal women without any androgenic effect, and no deleterious effects on blood vessels comprising continuously without interruption administering to said women, a combination of 0.5 to 3 mg of an estrogenic compound and 1.5 to 3.75 mg of nomegestrol acetate.

Hormonal composition consisting of an oestrogen compound and of a progestational compound

LH-RH peptide analogues, their uses and pharmaceutical compositions containing them

The invention relates to compounds of the formula:

19-nor-pregnene derivatives and pharmaceuticals containing such derivatives

LH-RH analogues with excellent affinity for LH-RH receptors, of the formula A.sub.1 -A.sub.2 -W-A.sub.3 -A.sub.4 -SPL-A.sub.5 -A.sub.6 -Pro-Z(I) in which:

Conformationally constrained LH-RH analogues, their uses and

Hormonal medicaments and their use for the correction of oestrogenic

Subcutaneous implants based on normegestrol derivatives

Growing community of inventors

Nice, France

Jacques Paris